Login / Signup

PD-L1 expression in extrahepatic cholangiocarcinoma.

Dirk WalterEva HerrmannAndreas A SchnitzbauerStefan ZeuzemMartin Leo HansmannJan Peveling-OberhagSylvia Hartmann
Published in: Histopathology (2017)
Only a small number of eCCA patients are PD-L1-positive, which might be important for future application of PD-1/PD-L1-targeted immune-modulating therapy in these patients. A small subgroup of eCCAs with PD-L1 expression and low lymphocytic infiltration showed more invasive growth and worse overall survival.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • prognostic factors
  • randomized controlled trial
  • cancer therapy
  • bone marrow
  • drug delivery
  • phase iii
  • double blind